Cross-topic event
Hamlet BioPharma Alpha1H Wins EMA Approval for Phase 3 Bladder Cancer Trial
Jun 29, 20262 reports
Jun 29, 2026
Sciencedesk view
Hamlet BioPharma Alpha1H Wins EMA Approval for Phase 3 Bladder Cancer Trial
Per Hamlet BioPharma on June 29, 2026, the European Medicines Agency (EMA) approved a Phase 3 clinical study of candidate Alpha1H in non-muscle invasive bladder…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
Hamlet BioPharma wins EMA approval to launch Phase III Alpha1H bladder cancer trial
Per a Hamlet BioPharma release on June 29, the company received European Medicines Agency (EMA) regulatory approval for a Phase III study of Alpha1H in non-musc…
READ THE DAY'S DIGEST →